X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
The proceeds will be utilized for the preparation of Stalicla’s pioneering precision Autism Spectrum Disorder (ASD) Phase 2 trial evaluating STP1, a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).
Lead Product(s): Ibudilast,Bumetanide
Therapeutic Area: Neurology Product Name: STP1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: $17.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 16, 2024
Details:
STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candidate for ASD-Phenotype 1.
Lead Product(s): Ibudilast,Bumetanide
Therapeutic Area: Neurology Product Name: STP1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Firefly Neuroscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2023
Details:
Bumetanide injection generic version of Bumex, is given to help treat fluid retention (edema) and swelling that is caused by congestive heart failure, liver disease, kidney disease, or other medical conditions.
Lead Product(s): Bumetanide
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
